Carmen Fava

Carmen Fava

UNVERIFIED PROFILE

Are you Carmen Fava?   Register this Author

Register author
Carmen Fava

Carmen Fava

Publications by authors named "Carmen Fava"

Are you Carmen Fava?   Register this Author

60Publications

1191Reads

43Profile Views

Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?

Haematologica 2019 May;104(5):862-864

Haematology Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.214445DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518890PMC
May 2019

Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?

Int J Mol Sci 2019 May 7;20(9). Epub 2019 May 7.

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20092249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540058PMC
May 2019

Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.

Curr Drug Targets 2017 ;18(4):389-395

Department of Clinical and Biological Sciences, University of Turin, regione Gonzole 10, 10043, Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389450117666160608120527DOI Listing
September 2017

The biology of CML supports second-generation TKIs as frontline treatment.

Clin Adv Hematol Oncol 2017 Apr;15(4):302-307

University of Turin, Mauriziano Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
April 2017

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.

Clin Lymphoma Myeloma Leuk 2016 08 1;16 Suppl:S96-S100. Epub 2016 Apr 1.

Department of Clinical and Biological Sciences, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano (TO), Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.03.008DOI Listing
August 2016

Ponatinib for chronic myeloid leukaemia: future perspectives.

Lancet Oncol 2016 05 12;17(5):546-7. Epub 2016 Apr 12.

Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30064-XDOI Listing
May 2016

BCR-ABL1 mutation ≠ ponatinib resistance.

Blood 2016 Feb;127(6):666-7

UNIVERSITY OF TURIN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-12-685149DOI Listing
February 2016

BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.

Cell Cycle 2015 ;14(7):973-9

a Department of Clinical and Biological Sciences; San Luigi Hospital ; Orbassano - Turin University ; Turin , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2015.1006970DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615112PMC
December 2015

Update on emerging treatments for chronic myeloid leukemia.

Expert Opin Emerg Drugs 2015 Jun 31;20(2):183-96. Epub 2015 Mar 31.

University of Turin, San Luigi Hospital, Department of Clinical and Biological Sciences , Orbassano 10043 , Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2015.1031217DOI Listing
June 2015

Milestones and monitoring.

Curr Hematol Malig Rep 2015 Jun;10(2):167-72

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, "San Luigi Gonzaga" University Hospital, 10043, Orbassano, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-015-0258-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445481PMC
June 2015

The choice of first-line chronic myelogenous leukemia treatment.

Ann Hematol 2015 Apr 27;94 Suppl 2:S123-31. Epub 2015 Mar 27.

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, "San Luigi Gonzaga" University Hospital, 10043, Orbassano, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2321-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375302PMC
April 2015

Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome.

World J Radiol 2014 Aug;6(8):583-8

Luciano Cardinale, Francesco Asteggiano, Federica Moretti, Federico Torre, Institute of Radiology, Department of Clinical and Biological Sciences, University of Turin, AOU S.Luigi Gonzaga, 10043 Orbassano, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4329/wjr.v6.i8.583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147438PMC
August 2014

Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.

Ther Drug Monit 2014 Jun;36(3):410-2

*Department of Biological and Clinical Sciences, S. Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy; and †Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000013DOI Listing
June 2014

Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.

Expert Opin Biol Ther 2014 Mar 3;14(3):287-99. Epub 2014 Jan 3.

University Turin, San Luigi Hospital, Division of Hematology and Internal Medicine, Department of Oncology , Orbassano - Turin , Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2014.867323DOI Listing
March 2014

Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.

Clin Lymphoma Myeloma Leuk 2013 Sep;13 Suppl 2:S272-5

Division of Haematology and Internal Medicine, Department of Clinical and Biological Science, University of Turin, Turin. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.05.017DOI Listing
September 2013

Chronic myeloid leukemia: state of the art in 2012.

Curr Oncol Rep 2012 Oct;14(5):379-86

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, 10043, Orbassano, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-012-0253-9DOI Listing
October 2012

Molecular resistance: an early indicator for treatment change?

Clin Lymphoma Myeloma Leuk 2012 Apr 28;12(2):79-87. Epub 2012 Jan 28.

University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2011.12.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539978PMC
April 2012

HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).

J Pharm Biomed Anal 2012 Feb 14;59:109-16. Epub 2011 Oct 14.

Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2011.10.003DOI Listing
February 2012

A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.

J Chromatogr Sci 2011 Nov-Dec;49(10):753-7

Clinical Pharmacology, Clinical and Biological Sciences Department, University of Turin, S. Luigi Hospital, Orbassano, TO, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/chrsci/49.10.753DOI Listing
January 2012

Practical monitoring of chronic myelogenous leukemia: when to change treatment.

J Natl Compr Canc Netw 2012 Jan;10(1):121-9

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, San Luigi Gonzaga University Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2012.0011DOI Listing
January 2012

Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?

Semin Hematol 2010 Oct;47(4):319-26

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2010.06.001DOI Listing
October 2010

Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.

Cancer Genet Cytogenet 2010 Jun;199(2):139-42

Oncohematology Unit, Department of Clinical and Experimental Medicine, University of Perugia, S. Maria Hospital, Via Tristano di Joannuccio 1, 05100 Terni, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergencyto.2010.02.008DOI Listing
June 2010

Standard management of patients with chronic myeloid leukemia.

Clin Lymphoma Myeloma 2009 ;9 Suppl 4:S382-90

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLM.2009.s.038DOI Listing
March 2010

Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.

Leuk Lymphoma 2009 Oct;50(10):1564-5

Division of Haematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190903216853DOI Listing
October 2009

Advances in the biology and therapy of patients with chronic myeloid leukaemia.

Best Pract Res Clin Haematol 2009 Sep;22(3):395-407

Department of Leukemia, The University of Texas, Unit 428, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2009.09.002DOI Listing
September 2009

Optimizing first-line therapy for patients with chronic myeloid leukemia.

Semin Hematol 2009 Apr;46(2 Suppl 3):S5-10

Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
April 2009

Development and targeted use of nilotinib in chronic myeloid leukemia.

Drug Des Devel Ther 2009 Feb 6;2:233-43. Epub 2009 Feb 6.

Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761189PMC
February 2009

Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

Neurol Sci 2008 Jun 9;29(3):185-7. Epub 2008 Jul 9.

Centro di Riferimento Regionale Sclerosi Multipla & Neurobiologia Clinica, Aou S Luigi Gonzaga, Regione Gonzole 10, Orbassano TO, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10072-008-0934-1DOI Listing
June 2008

Corticosteroids can reverse severe imatinib-induced hepatotoxicity.

Haematologica 2006 Jun;91(6 Suppl):ECR27

Divisione di Ematologia dell'Università degli Studi di Torino, Molinette Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
June 2006